What treatments are primarily indicated for genital arousal disorder (FGAD)?

What treatments are primarily indicated for genital arousal disorder (FGAD)?

• A. L-arginine, topical alprostadil
• B. Wellbutrin, estrogen therapy
• C. Selective serotonin reuptake inhibitors
• D. Phosphodiesterase inhibitors

Answer: (A)

Genital arousal disorder (FGAD) is characterized by a persistent inability to attain or maintain adequate genital arousal. The treatments indicated for FGAD primarily focus on enhancing blood flow and promoting sexual arousal. L-arginine, an amino acid, is known to improve circulation and increase nitric oxide availability, which can effectively enhance blood flow to the genital region. This can facilitate genital arousal and alleviate symptoms associated with FGAD. Topical alprostadil, a prostaglandin E1, specifically acts by dilating blood vessels and increasing blood flow to the genital area, again supporting arousal. The combination of L-arginine and topical alprostadil directly targets the physiological mechanisms involved in genital arousal, making them highly suitable treatments for FGAD. In contrast, other options do not specifically address the underlying circulatory issues involved in FGAD. While Wellbutrin and estrogen therapy may be beneficial for mood and hormone levels, they do not directly resolve genital arousal difficulties. Selective serotonin reuptake inhibitors may affect sexual function and arousal negatively in some individuals rather than providing adequate arousal. Phosphodiesterase inhibitors, while beneficial for erectile dysfunction, are not typically indicated for genital arousal disorder in women

Genital arousal disorder (FGAD) is characterized by a persistent inability to attain or maintain adequate genital arousal. The treatments indicated for FGAD primarily focus on enhancing blood flow and promoting sexual arousal. L-arginine, an amino acid, is known to improve circulation and increase nitric oxide availability, which can effectively enhance blood flow to the genital region. This can facilitate genital arousal and alleviate symptoms associated with FGAD.

Topical alprostadil, a prostaglandin E1, specifically acts by dilating blood vessels and increasing blood flow to the genital area, again supporting arousal. The combination of L-arginine and topical alprostadil directly targets the physiological mechanisms involved in genital arousal, making them highly suitable treatments for FGAD.

In contrast, other options do not specifically address the underlying circulatory issues involved in FGAD. While Wellbutrin and estrogen therapy may be beneficial for mood and hormone levels, they do not directly resolve genital arousal difficulties. Selective serotonin reuptake inhibitors may affect sexual function and arousal negatively in some individuals rather than providing adequate arousal. Phosphodiesterase inhibitors, while beneficial for erectile dysfunction, are not typically indicated for genital arousal disorder in women